Effexor
NDC 16590-085
View NDC Profile UNII Mappings and RxNorm Concepts.
Product Information
This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
Effexor is a NDA-approved product labeled by Stat Rx Usa. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a orange product. This product entry covers the primary NDC 16590-085 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
NDC Product Code:
16590-085
Proprietary Name:
Effexor XR
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Code Navigator:
Labeler & Regulatory Data
Labeler Name: [5]
Labeler Code:
16590
Product Label ID:
FDA Application Number: [6]
NDA020699
Marketing Category: [8]
NDA - A product marketed under an approved New Drug Application.
Marketing Timeline
Start Marketing Date: [9]
11-01-1997
Listing Expiration Date: [11]
12-31-2017
Exclude Flag: [12]
I
Product Characteristics
Color(s):
ORANGE (C48331 - PEACH)
GRAY (C48324)
GRAY (C48324)
Shape:
CAPSULE (C48336)
Size(s):
16 MM
Imprint(s):
W;EFFEXORXR;375 Score:
1
Code Structure Chart
Product Details
What is NDC 16590-085?
The NDC code 16590-085 is assigned by the FDA to the product Effexor XR. This pharmaceutical product is labeled by Stat Rx Usa and is currently categorized as listed product. In terms of distribution, this product is available in 2 different package configurations. The associated package NDC(s) include: 16590-085-30, 16590-085-60. Beyond standard identification, this entry provides technical data including pharmacologic classes, UNII ingredient references, and RxNorm cross-referencing for healthcare systems.
What are the uses of this product?
INDICATIONS AND USAGEMajor Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules
is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was
established in 8- and 12-week controlled trials of adult outpatients whose
diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major
depressive disorder (see Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively
persistent (nearly every day for at least 2 weeks) depressed mood or the loss of
interest or pleasure in nearly all activities, representing a change from
previous functioning, and includes the presence of at least five of the
following nine symptoms during the same two-week period: depressed mood,
markedly diminished interest or pleasure in usual activities, significant change
in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or
retardation, increased fatigue, feelings of guilt or worthlessness, slowed
thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major
depressive disorder in adult inpatients meeting diagnostic criteria for major
depressive disorder with melancholia was established in a 4-week controlled
trial (see Clinical
Trials). The safety and efficacy of Effexor XR in hospitalized
depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive
disorder for up to 26 weeks following 8 weeks of acute treatment was
demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate
release) in maintaining a response in patients with recurrent major depressive
disorder who had responded and continued to be improved during an initial 26
weeks of treatment and were then followed for a period of up to 52 weeks was
demonstrated in a second placebo-controlled trial (see Clinical Trials). Nevertheless,
the physician who elects to use Effexor/Effexor XR for extended periods should
periodically re-evaluate the long-term usefulness of the drug for the individual
patient (see DOSAGE AND
ADMINISTRATION). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety
Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the
stress of everyday life usually does not require treatment with an anxiolytic.
The efficacy of Effexor XR in the treatment of GAD was established in 8-week
and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD
according to DSM-IV criteria (see Clinical Trials). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety
and worry (apprehensive expectation) that is persistent for at least 6 months
and which the person finds difficult to control. It must be associated with at
least 3 of the following 6 symptoms: restlessness or feeling keyed up or on
edge, being easily fatigued, difficulty concentrating or mind going blank,
irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month
clinical trials in patients with GAD, the physician who elects to use Effexor XR
for extended periods should periodically re-evaluate the long-term usefulness of
the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety
Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent
fear of 1 or more social or performance situations in which the person is
exposed to unfamiliar people or to possible scrutiny by others. Exposure to the
feared situation almost invariably provokes anxiety, which may approach the
intensity of a panic attack. The feared situations are avoided or endured with
intense anxiety or distress. The avoidance, anxious anticipation, or distress in
the feared situation(s) interferes significantly with the person's normal
routine, occupational or academic functioning, or social activities or
relationships, or there is a marked distress about having the phobias. Lesser
degrees of performance anxiety or shyness generally do not require
psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was
established in four 12-week and one 6-month placebo-controlled trials in adult
outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials). Although the effectiveness of Effexor XR has been demonstrated in a 6-month
clinical trial in patients with Social Anxiety Disorder, the physician who
elects to use Effexor XR for extended periods should periodically re-evaluate
the long-term usefulness of the drug for the individual patient (see DOSAGE AND
ADMINISTRATION). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with
or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by
the occurrence of unexpected panic attacks and associated concern about having
additional attacks, worry about the implications or consequences of the attacks,
and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic
attacks, ie, a discrete period of intense fear or discomfort, in which four (or
more) of the following symptoms develop abruptly and reach a peak within 10
minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2)
sweating; 3) trembling or shaking; 4) sensations of shortness of breath or
smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or
abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9)
derealization (feelings of unreality) or depersonalization (being detached from
oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias
(numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established
in two 12-week placebo-controlled trials in adult outpatients with panic
disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in
panic disorder among responders following 12 weeks of open-label acute treatment
was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical
Trials). Nevertheless, the physician who elects to use Effexor
XR for extended periods should periodically re-evaluate the long-term usefulness
of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO)
- VENLAFAXINE (UNII: GRZ5RCB1QG) (Active Moiety)
What is the NDC to RxNorm Crosswalk for this product?
RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
- RxCUI: 313581 - venlafaxine HCl 150 MG 24HR Extended Release Oral Capsule
- RxCUI: 313581 - 24 HR venlafaxine 150 MG Extended Release Oral Capsule
- RxCUI: 313581 - venlafaxine (as venlafaxine HCl) 150 MG 24 HR Extended Release Oral Capsule
- RxCUI: 313583 - venlafaxine HCl 37.5 MG 24HR Extended Release Oral Capsule
- RxCUI: 313583 - 24 HR venlafaxine 37.5 MG Extended Release Oral Capsule
* Please review the full disclaimer at the bottom of this page.
Product & Regulatory Definitions
What is the Labeler Name? Name of Company corresponding to the labeler code segment of the Product NDC.
What is the FDA Application Number? This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
What is the Marketing Category? Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
What is the Start Marketing Date? This is the date that the labeler indicates was the start of its marketing of the drug product.
What is the Listing Expiration Date? This is the date when the listing record will expire if not updated or certified by the product labeler.
What is the NDC Exclude Flag? This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".